retatrutide triple agonist gip glp-1 glucagon phase 2 obesity Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide is gaining attention in
Description
Clinical data shows that GLP-1 RAs can reduce the risk of major adverse cardiovascular events (MACE) in diabetic patients
Side effects and tolerability: Nausea, vomiting, or digestive issues sometimes lead patients to stop treatment
C.PengS
At a 4mg weekly total, each injection is approximately 1.33mg (13.3 IU at 10mg/mL)
FAQ 7: Can I get my GLP-1 prescription refilled while traveling internationally
